In addition, targeting of the purinergic pathway via a blockade of CD39 or A2AR augmented the NK cell-mediated lysis of the AML cells (anti-CD39 vs. control for MV-4-11 p = 0.0039, for TF-1 p = 0.0039 and for OCI-AML3 p = 0.0039 and anti-A2AR vs. control for MV-4-11 p = 0.0039, for TF-1 p = 0.0195 and for OCI-AML3 p = 0.0039; Figure 5C). The gene discussed is RUNX2; the disease is acute myeloid leukemia.